Bruner C A, Webb R C
Department of Physiology, University of Michigan Medical School, Ann Arbor 48109-0622.
J Hypertens. 1989 Jan;7(1):31-5. doi: 10.1097/00004872-198901000-00005.
Isolated tail arteries from stroke-prone spontaneously hypertensive rats (SHRSP), but not from normotensive Wistar-Kyoto rats (WKY), exhibit oscillatory contractions in response to norepinephrine. Previous studies indicate that the mechanism for these oscillations involves altered membrane calcium and/or potassium handling, and that this vascular change is a genetic defect associated with hypertension in SHRSP. The purpose of this experiment was to determine whether treatment of SHRSP with the calcium entry blocker felodipine would alter oscillatory activity. Adult SHRSP and WKY rats were treated orally with felodipine for 8 weeks. Felodipine treatment produced a significant decrease in blood pressure in SHRSP (control SHRSP: 240 +/- 7 mmHg, n = 6; felodipine-treated SHRSP: 164 +/- 8 mmHg, n = 5, P less than 0.05; tail-cuff method). Helically-cut tail artery strips from all rats were mounted in tissue baths for isometric force recording and exposed to norepinephrine (6 x 10(-9) to 6 x 10(-6) mol/l) for 20 min at each concentration. Oscillatory activity was defined as the sum of the magnitudes of all phasic contractions occurring during the final 10 min of norepinephrine incubation. Oscillatory activity was markedly reduced in tail arteries from felodipine-treated SHRSP when compared with control SHRSP. Felodipine also inhibited oscillatory activity when added directly to the tissue bath. It seems, therefore, that felodipine may lower blood pressure in SHRSP, at least in part, by correcting the genetic defect responsible for oscillatory activity.
来自易中风自发性高血压大鼠(SHRSP)的离体尾动脉,而非正常血压的Wistar-Kyoto大鼠(WKY)的离体尾动脉,对去甲肾上腺素会产生振荡性收缩。先前的研究表明,这些振荡的机制涉及膜钙和/或钾处理的改变,并且这种血管变化是与SHRSP高血压相关的遗传缺陷。本实验的目的是确定用钙通道阻滞剂非洛地平治疗SHRSP是否会改变振荡活动。成年SHRSP和WKY大鼠口服非洛地平8周。非洛地平治疗使SHRSP的血压显著降低(对照SHRSP:240±7 mmHg,n = 6;非洛地平治疗的SHRSP:164±8 mmHg,n = 5,P<0.05;尾袖法)。将所有大鼠螺旋形切割的尾动脉条安装在组织浴中进行等长力记录,并在每个浓度下暴露于去甲肾上腺素(6×10⁻⁹至6×10⁻⁶ mol/l)20分钟。振荡活动定义为去甲肾上腺素孵育最后10分钟内发生的所有相位收缩幅度的总和。与对照SHRSP相比,非洛地平治疗的SHRSP尾动脉中的振荡活动明显降低。直接添加到组织浴中时,非洛地平也抑制振荡活动。因此,似乎非洛地平可能至少部分地通过纠正导致振荡活动的遗传缺陷来降低SHRSP的血压。